Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: A long-term safety study

Raffaele Parrozzani, Daniela Lazzarini, Ernesto Alemany-Rubio, Francesca Urban, Edoardo Midena

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background/aims: The aim of this study was to evaluate the long-term corneal toxicity of topical chemotherapy with 1% 5-fluorouracil (5-FU) as a sole or adjuvant treatment of ocular surface squamous neoplasia (OSSN). Methods: Forty-one consecutive cases of OSSN were included in this prospective study. Patients underwent topical chemotherapy with 1% 5-FU four times/day for 4 weeks (one course). Adjunctive courses were repeated until clinical and cytological tumour regression. Clinical confocal microscopy was used to check for 5-FU long-term corneal toxicity. Results: Mean follow-up was 89.7±14.4 months (range 63-122 months). Twenty-two patients (53.7%) underwent topical 5-FU as a sole treatment, and 19 patients (46.3%) as adjuvant and/or debulking therapy. The mean number of 5-FU cycles was 1.9 (range 1-5 cycles). Three tumours (7.3%) treated with 5-FU alone recurred during follow-up. Recurrences were successfully treated with additional 5-FU courses. Clinical confocal microscopy showed no long-term difference between the treated eye and fellow (control) eye in: endothelial cells count, pleomorphism and polymegatism, anterior stromal keratocyte density, sub-basal nerve plexus fibre number, density, and beadings and central cornea epithelium thickness (p=NS). Conclusion: Topical 5-FU, as a sole or combined therapy, must be considered a long-term safe and effective treatment for patients affected by OSSN.

Original languageEnglish
Pages (from-to)355-359
Number of pages5
JournalBritish Journal of Ophthalmology
Volume95
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Fluorouracil
Safety
Neoplasms
Confocal Microscopy
Therapeutics
Drug Therapy
Nerve Fibers
Cornea
Epithelium
Endothelial Cells
Cell Count
Prospective Studies
Recurrence

ASJC Scopus subject areas

  • Ophthalmology
  • Cellular and Molecular Neuroscience
  • Sensory Systems

Cite this

Topical 1% 5-fluorouracil in ocular surface squamous neoplasia : A long-term safety study. / Parrozzani, Raffaele; Lazzarini, Daniela; Alemany-Rubio, Ernesto; Urban, Francesca; Midena, Edoardo.

In: British Journal of Ophthalmology, Vol. 95, No. 3, 03.2011, p. 355-359.

Research output: Contribution to journalArticle

Parrozzani, Raffaele ; Lazzarini, Daniela ; Alemany-Rubio, Ernesto ; Urban, Francesca ; Midena, Edoardo. / Topical 1% 5-fluorouracil in ocular surface squamous neoplasia : A long-term safety study. In: British Journal of Ophthalmology. 2011 ; Vol. 95, No. 3. pp. 355-359.
@article{8b20db6f40a14a5c9e09dad2689b8ff4,
title = "Topical 1{\%} 5-fluorouracil in ocular surface squamous neoplasia: A long-term safety study",
abstract = "Background/aims: The aim of this study was to evaluate the long-term corneal toxicity of topical chemotherapy with 1{\%} 5-fluorouracil (5-FU) as a sole or adjuvant treatment of ocular surface squamous neoplasia (OSSN). Methods: Forty-one consecutive cases of OSSN were included in this prospective study. Patients underwent topical chemotherapy with 1{\%} 5-FU four times/day for 4 weeks (one course). Adjunctive courses were repeated until clinical and cytological tumour regression. Clinical confocal microscopy was used to check for 5-FU long-term corneal toxicity. Results: Mean follow-up was 89.7±14.4 months (range 63-122 months). Twenty-two patients (53.7{\%}) underwent topical 5-FU as a sole treatment, and 19 patients (46.3{\%}) as adjuvant and/or debulking therapy. The mean number of 5-FU cycles was 1.9 (range 1-5 cycles). Three tumours (7.3{\%}) treated with 5-FU alone recurred during follow-up. Recurrences were successfully treated with additional 5-FU courses. Clinical confocal microscopy showed no long-term difference between the treated eye and fellow (control) eye in: endothelial cells count, pleomorphism and polymegatism, anterior stromal keratocyte density, sub-basal nerve plexus fibre number, density, and beadings and central cornea epithelium thickness (p=NS). Conclusion: Topical 5-FU, as a sole or combined therapy, must be considered a long-term safe and effective treatment for patients affected by OSSN.",
author = "Raffaele Parrozzani and Daniela Lazzarini and Ernesto Alemany-Rubio and Francesca Urban and Edoardo Midena",
year = "2011",
month = "3",
doi = "10.1136/bjo.2010.183244",
language = "English",
volume = "95",
pages = "355--359",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Topical 1% 5-fluorouracil in ocular surface squamous neoplasia

T2 - A long-term safety study

AU - Parrozzani, Raffaele

AU - Lazzarini, Daniela

AU - Alemany-Rubio, Ernesto

AU - Urban, Francesca

AU - Midena, Edoardo

PY - 2011/3

Y1 - 2011/3

N2 - Background/aims: The aim of this study was to evaluate the long-term corneal toxicity of topical chemotherapy with 1% 5-fluorouracil (5-FU) as a sole or adjuvant treatment of ocular surface squamous neoplasia (OSSN). Methods: Forty-one consecutive cases of OSSN were included in this prospective study. Patients underwent topical chemotherapy with 1% 5-FU four times/day for 4 weeks (one course). Adjunctive courses were repeated until clinical and cytological tumour regression. Clinical confocal microscopy was used to check for 5-FU long-term corneal toxicity. Results: Mean follow-up was 89.7±14.4 months (range 63-122 months). Twenty-two patients (53.7%) underwent topical 5-FU as a sole treatment, and 19 patients (46.3%) as adjuvant and/or debulking therapy. The mean number of 5-FU cycles was 1.9 (range 1-5 cycles). Three tumours (7.3%) treated with 5-FU alone recurred during follow-up. Recurrences were successfully treated with additional 5-FU courses. Clinical confocal microscopy showed no long-term difference between the treated eye and fellow (control) eye in: endothelial cells count, pleomorphism and polymegatism, anterior stromal keratocyte density, sub-basal nerve plexus fibre number, density, and beadings and central cornea epithelium thickness (p=NS). Conclusion: Topical 5-FU, as a sole or combined therapy, must be considered a long-term safe and effective treatment for patients affected by OSSN.

AB - Background/aims: The aim of this study was to evaluate the long-term corneal toxicity of topical chemotherapy with 1% 5-fluorouracil (5-FU) as a sole or adjuvant treatment of ocular surface squamous neoplasia (OSSN). Methods: Forty-one consecutive cases of OSSN were included in this prospective study. Patients underwent topical chemotherapy with 1% 5-FU four times/day for 4 weeks (one course). Adjunctive courses were repeated until clinical and cytological tumour regression. Clinical confocal microscopy was used to check for 5-FU long-term corneal toxicity. Results: Mean follow-up was 89.7±14.4 months (range 63-122 months). Twenty-two patients (53.7%) underwent topical 5-FU as a sole treatment, and 19 patients (46.3%) as adjuvant and/or debulking therapy. The mean number of 5-FU cycles was 1.9 (range 1-5 cycles). Three tumours (7.3%) treated with 5-FU alone recurred during follow-up. Recurrences were successfully treated with additional 5-FU courses. Clinical confocal microscopy showed no long-term difference between the treated eye and fellow (control) eye in: endothelial cells count, pleomorphism and polymegatism, anterior stromal keratocyte density, sub-basal nerve plexus fibre number, density, and beadings and central cornea epithelium thickness (p=NS). Conclusion: Topical 5-FU, as a sole or combined therapy, must be considered a long-term safe and effective treatment for patients affected by OSSN.

UR - http://www.scopus.com/inward/record.url?scp=79952031911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952031911&partnerID=8YFLogxK

U2 - 10.1136/bjo.2010.183244

DO - 10.1136/bjo.2010.183244

M3 - Article

C2 - 20693564

AN - SCOPUS:79952031911

VL - 95

SP - 355

EP - 359

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 3

ER -